Acurx awarded patent covering DNA Polymerase IIIC inhibitors by USPTO

Acurx (ACXP) Pharmaceuticals announced that the U.S. States Patent and Trademark Office has granted a new U.S. patent, US 12,534,470. This latest patent, which covers DNA Polymerase IIIC inhibitors including compositions-of-matter, methods of use, and pharmaceutical compositions, further strengthens Acurx’s intellectual property portfolio and represents the most recent addition to its expanding series of granted patents in the U.S. and abroad. To date, Acurx has secured four U.S. patents, along with granted patents in Israel, Japan, India, and Australia, all of which protect key aspects of the Company’s ACX-375C program targeting DNA Polymerase IIIC. Additional country-level patent applications remain under review.